Bengaluru, January 26, 2016: Positive Bioscience announced today the launch of its next generation product, Positive Select, a RNA sequencing test for Cancer treatment. Positive Select is the latest arsenal in fighting against cancer and is intended to aid Oncologists select the best treatment for cancer patients. Positive Select is based on whole RNA sequencing which is the latest technology available in the world and enhances the utility of comprehensive genomics profile manifold bringing Genomics test closer to clinical practice. With this Positive Bioscience becomes the first company in India to offer whole RNA sequencing test commercially for cancer.
“By launching Positive Select, Positive Bioscience is again demonstrating its commitment to innovation and making cutting edge molecular information available to oncology community in India and worldwide,” said Samarth Jain, Chief Executive Officer, Positive Bioscience. “Cancer is driven by genomic alterations. Positive Select detects genomic alterations in all 25,000 genes and recommends treatment options with best probability of response as compared to recommendations based on testing of 4-5 genes through conventional testing. We expect that Positive Select will revolutionise molecular diagnostics in a way CT scan revolutionised imaging diagnostics when X Ray was a norm.”
“In this era of Precision Oncology, RNA sequencing is a recent advancement in diagnostic technology, offering the most comprehensive genetic information on various alterations and the level of expression on thousands of genes in a single step. The information can be used to select the best treatment option with least side effects. Said “Dr Amit Verma, Consultant – Molecular Oncology & Cancer Genetics, Max Super Speciality Hospitals Saket, New Delhi.
Corporate Comm India(CCI Newswire)
